首页 癌症遗传学(usCGIX)-基本信息

癌症遗传学(usCGIX)-基本信息

日报更新时间:

周报更新时间:01-23 11:54

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

中文名称:癌症遗传学


英文名称:Cancer Genetics


简介:Cancer Genetics, Inc.于1999年4月8日在美国特拉华州注册成立,并在新泽西州的卢瑟福设有办事处和实验室


电话:1-201-5289200


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

癌症遗传学公司的测试使医生能够通过提供基因组信息来诊断,监测和告知癌症治疗,从而个性化每个患者的临床管理;并使参与肿瘤学和免疫肿瘤学试验的生物技术和制药公司能够通过提供影响受试者对治疗反应的基因组因素的信息来选择候选人群并减少药物不良反应。 Cancer Genetics公司的生物制药服务通过一系列基于分子和生物标记的测试服务,定制化验开发和试验设计咨询,为公司提供定制的患者分层和治疗选择解决方案。 Cancer Genetics临床服务提供有关癌症的诊断,预后和预测治疗结果的信息,以指导患者管理。 Cancer Genetics的发现服务为公司和研究人员提供工具和测试方法,以识别和开发用于疾病诊断和治疗的新化合物和基于分子的生物标记物。癌症遗传学公司为医院,癌症中心,诊所,学术机构和政府资助的研究机构以及进行临床试验的制药和生物技术公司提供服务。癌症遗传学公司与肿瘤中心和社区医院合作开发其专有的诊断测试;并与Cellaria合作开发精密医疗工具和平台技术,以支持新的癌症治疗方法的开发。

交易日期 交易人 职位 类型 交易份额 价格
2019-01-30 Cannon (Edmund) Director Buy 43479 0.23
2019-01-30 Roberts (John A) Chief Executive Officer Buy 185436 0.23
2019-01-30 Miles (Michael Glenn) Chief Financial Officer Buy 150000 0.23
2019-01-30 Pappajohn (John G) Director Buy 1000000 0.23
2019-01-13 Roberts (John A) Chief Executive Officer Buy 100000 0.23
2019-01-13 Harris Geoffrey E Director Buy 100000 0.23
2019-01-13 Pappajohn (John G) Director Buy 1000000 0.23
2017-12-14 Roberts (John A) Chief Operating Officer Buy 12200 2.00
2017-12-07 Pappajohn (John G) Director and Beneficial Owner Buy 150000 1.86
2017-09-27 McLeod (Howard) Director Buy 2500 --
2017-09-27 Pappajohn (John G) Director and Beneficial Owner Buy 2500 --
2017-09-27 Prendergast (Franklyn G) Director Buy 2500 --
2017-09-27 Harris Geoffrey E Director Buy 2500 --
2017-09-27 Chaganti (Raju S K) Director Buy 2500 --
2017-09-27 Cannon (Edmund) Director Buy 2500 --
2017-09-27 Welsh Michael J Director Buy 2500 --
2017-08-17 Pappajohn (John G) Director and Beneficial Owner Buy 20000 3.28
2017-08-16 Pappajohn (John G) Director and Beneficial Owner Buy 66185 3.24

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Morgan Stanley Smith Barney LLC 12542 0.02% -1250 -9.06% 2019-03-31
Diker Management LLC 64365 0.11% -- -- 2019-03-31
Fairbanks Capital Management, Inc. 82900 0.14% -- -- 2019-03-31
Vanguard Group Inc 194041 0.34% 14690 8.19% 2019-03-31
Virtu Financial LLC 201080 0.35% 201080 -- 2019-03-31
Fidelity Management & Research Company 217946 0.38% -- -- 2019-07-31
Geode Capital Management, LLC 221803 0.38% -221803 -50.00% 2019-03-31
Renaissance Technologies Corp 2007229 3.47% 1098515 120.89% 2019-03-31
Perkins Capital Management Inc 3136528 5.43% 2718278 649.92% 2019-03-31
Granahan Investment Management Inc 60501 0.10% -2800 -4.42% 2019-07-31
Satuit Capital Management, LLC 50000 0.09% -- -- 2019-07-31
Northern Trust Investments Inc 42249 0.07% 699 1.68% 2019-07-31
Morgan Stanley - Brokerage Accounts 12542 0.02% -1250 -9.06% 2019-03-31
Bahl & Gaynor Inc. 20000 0.03% 10000 100.00% 2019-03-31
Ladenburg Thalmann FI Services Inc 21794 0.04% 4294 24.54% 2019-03-31
Wedbush Morgan Securities Inc 24022 0.04% -14510 -37.66% 2019-03-31
Northern Trust Investments N A 32576 0.06% -- -- 2019-03-31
Northern Trust Corp 32576 0.06% -- -- 2019-03-31
Royal Bank of Canada 34000 0.06% 34000 -- 2019-03-31
First Premier Bank 36725 0.06% 36725 -- 2019-03-31
Granahan Investment Management Inc.. 272818 0.47% -5442 -1.96% 2018-12-31
Panagora Asset Management Inc 37319 0.06% -706 -1.86% 2018-12-31
BlackRock Asset Management Canada Ltd 27954 0.05% 304 1.10% 2019-05-31
TWO SIGMA SECURITIES, LLC 19265 0.03% -4176 -17.81% 2018-12-31
Sunrise Partners LLC 33400 0.06% 33400 -- 2018-12-31
Susquehanna Financial Group, LLLP 27592 0.05% 27592 -- 2018-12-31
Susquehanna International Group, LLP 27592 0.05% 27592 -- 2018-12-31
UBS Group AG 19242 0.03% 15358 395.42% 2018-12-31
Citadel Advisors Llc 33165 0.06% 33165 -- 2018-09-30
Vassalluzzo Scott J 23175 0.06% 23175 -- 2018-09-30
Stonepine Capital Management Llc 614411 2.21% -777196 -55.85% 2018-09-30
Seacrest Wealth Management, LLC 11000 0.04% 5000 83.33% 2018-06-30
Dimensional Fund Advisors LP 11966 0.04% -2741 -18.64% 2018-11-30
Vanguard Investments Australia Ltd 14502 0.05% -- -- 2018-11-30
Jacobs Levy Equity Management, Inc. 16489 0.06% -- -- 2018-03-31
Dimensional Fund Advisors, Inc. 19866 0.07% 19866 -- 2018-03-31
Spark Investment Management LLC 11600 0.04% 11600 -- 2018-03-31
Court Place Advisors LLC 10000 0.04% -- -- 2018-06-30
Credit Suisse First Boston (CSFB) 10090 0.04% 10090 -- 2018-06-30
Mellon Capital Management Corporation 7110 0.03% 1628 29.70% 2018-06-30
Ladenburg Thalmann Asset Management Inc 4500 0.03% -- -- 2018-06-30
UBS Securities LLC 8476 0.03% -52378 -86.07% 2018-06-30
Bankinter Gesti¨?n de Activos SGIIC 3003 0.01% 2 0.07% 2017-12-31
Guggenheim Funds Investment Advisors LLC 6547 0.03% -- -- 2018-09-14
BlackRock Inc 5433 0.02% -39487 -87.91% 2018-06-30
Wells Fargo Advisors, LLC 1800 0.01% -8000 -81.63% 2018-06-30
Wells Fargo Bank NA 7000 0.03% 4000 133.33% 2018-03-31
HRT FINANCIAL LLC 26211 0.09% 3012 12.98% 2018-03-31
Sabby Management LLC 942491 4.98% -139009 -12.85% 2016-12-31
BlackRock Fund Advisors 42036 0.19% 2 -- 2018-03-22
Thompson Davis & Co Inc 46975 0.19% -64325 -57.79% 2017-09-30
Pnc Bank, National Association 6000 0.02% -- -- 2017-09-30
SWK Holdings Corp 736076 3.90% -- -- 2016-11-14
BMO Asset Management Inc 12106 0.05% -2508 -17.16% 2017-09-30
Eagle Global Advisors, LLC 22170 0.11% 22170 -- 2017-06-30
Empery Asset Management, LP 833300 6.10% -- -- 2015-12-31
Frigate Ventures LP 271722 1.44% 271722 -- 2016-09-30
Tocqueville Asset Management L.P. 23800 0.13% -23800 -50.00% 2016-09-30
Brown Investment Advisory Incorporated 16000 0.08% -2000 -11.11% 2016-09-30
Sterneck Capital Management LLC 14370 0.08% -380 -2.58% 2016-09-30
Merrill Lynch & Co Inc 10191 0.05% 9647 1773.35% 2016-09-30
Next Financial Group Inc 7500 0.04% 7500 -- 2016-09-30
Bank of Montreal 648861 3.00% 5054627 0.10% 1999-11-30
John Pappajohn 1514289 3.00% 11796311 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
iShares Core S&P US Total Mkt ETF CADH -- -- -16 -100.00% 2019-07-31
Vanguard Extended Market Index Fund 194041 0.34% -- -- 2019-06-30
Granahan US Small Cap Discoveries Fund 60501 0.10% -2800 -4.42% 2018-12-31
Satuit Capital US Emerging Companies Fd 50000 0.09% -- -- 2018-11-30
NT Ext Equity Market Index Fund - L 17068 0.03% -- -- 2019-06-30
NT Extended Equity Market Idx Fund - NL 13428 0.02% -- -- 2019-06-30
NT Ext Equity Mkt Fd - DC - NL 9608 0.02% 699 7.85% 2019-06-30
iShares Core S&P Total US Stock Mkt ETF 7206 0.01% -- -- 2019-07-30
Fidelity 7133 0.01% -- -- 2019-06-30
NT US Market Cap Index Fund - Lending 2080 -- -- -- 2019-06-30
NT US Market Cap Index Fund - NL 65 -- -- -- 2018-12-31
Invesco Wilshire Micro-Cap ETF -- -- -4877 -100.00% 2019-02-22
BNYM Mellon SL Mkt Completion Fd -- -- -1540 -100.00% 2019-06-30
BNYM Mellon NSL Mkt Completion Fd Instl -- -- -5248 -100.00% 2019-06-30
iShares Core MSCI AllCntry Wld exCan ETF -- -- -7 -100.00% 2019-07-25
Vanguard Balanced Index Fund -- -- -23618 -100.00% 2018-12-31
Vanguard Instl Total Stock Market Idx Fd -- -- -31225 -100.00% 2018-12-31
iShares Core Growth ETF Portfolio -- -- -31 -100.00% 2019-07-25
NT Ext Equity Mkt Idx Fd - DC - NL 9608 0.02% 699 7.85% 2019-06-30
Kaldi Capital SICAV 3001 0.01% 2 0.07% 2018-09-30
iShares Core S&P US Total Market ETF 225 -- 12 5.63% 2019-06-28
iShares Core Balanced ETF Portfolio 17 -- 1 6.25% 2019-06-28
Vanguard Total Stock Market Index Fund -- -- -357272 -100.00% 2018-12-31
BNYM Mellon NSL Market Completion Fund 5248 0.01% 5146 5045.10% 2019-03-31
BNYM Mellon SL Market Completion Fund 1540 -- -3880 -71.59% 2019-03-31
The Vanguard Total Stock Market Index -- -- -3400 -100.00% 2018-06-30
1290 VT Micro Cap Portfolio -- -- -2676 -100.00% 2018-06-30
BNY Mellon Market Completion Fund 102 -- -1630 -94.11% 2018-12-31
iShares Micro-Cap ETF 4212 0.01% -41887 -90.86% 2018-06-22
DFA Tax-Managed US Targeted Value Port -- -- -2066 -100.00% 2018-04-30
DFA US Micro Cap Portfolio -- -- -1400 -100.00% 2018-04-30
DFA US Small Cap Portfolio -- -- -8500 -100.00% 2018-04-30
Vanguard Extended Market Idx Inv 179351 0.65% -- -- 2018-07-31
Vanguard Instl Ttl Stk Mkt Idx InstlPls 31225 0.11% -- -- 2018-07-31
Vanguard Balanced Index Inv 17202 0.06% -- -- 2018-07-31
Vanguard Total Stock Mkt Idx 14502 0.05% -- -- 2018-07-31
Fidelity Spartan 9725 0.04% -- -- 2018-07-31
Wilshire Micro-Cap ETF 6547 0.03% -- -- 2018-09-14
iShares Core S&P Total US Stock Mkt 5543 0.02% -- -- 2018-09-12
BNY Mellon EB DL Mkt Completion 5379 0.02% -- -- 2018-06-30
BNY Mellon Market Completion Fund UC1 1731 0.01% 1628 1580.58% 2018-03-31
Satuit Capital US Emerging Companies A 50000 -- -- -- 2018-07-31
AXA/Lord Abbett Micro Cap K 2676 0.01% -- -- 2018-05-31
iShares Micro-Cap 46099 0.17% -- -- 2018-06-21
DFA US Small Cap I 8500 0.03% -- -- 2018-03-31
DFA Tax-Managed US Targeted Value 2066 0.01% -2741 -57.02% 2018-03-31
DFA US Micro Cap I 1400 0.01% -- -- 2018-03-31
Tocqueville Opportunity 15000 0.08% -8800 -36.97% 2016-12-31
AllianzGI Ultra Micro Cap Fund 58548 0.60% -- -- 2015-09-30
Balter Long/Short Equity Fund 49542 0.50% 6520 15.20% 2015-07-31
Allianz US Ultra Micro Cap 30303 0.30% -- -- 2015-08-31
CF Richmond Core Fd 30000 0.30% 18000 150.00% 2015-07-31
Fidelity Spartan® Extended Mkt Indx Fd 27876 0.30% -- -- 2015-09-30
Royce Value Trust 17400 0.20% -39500 -69.40% 2015-09-30
Cornerstone Advisors Glbl Public Eq Fund 17374 0.20% -- -- 2015-09-30
Jacob Micro Cap Growth Fund 14954 0.20% -5000 -25.10% 2015-09-30
Westcore Micro Cap Opportunity Fund 14141 0.10% -- -- 2015-10-31
Fidelity Spartan® Total Market Idx Fund 9725 0.10% -- -- 2015-09-30
Turner Medical Sciences Long/Short 92730 0.90% -- -- 2015-09-30

John Pappajohn Mr. John Pappajohn is an Independent Director at MYnd Analytics, Inc., a Non-Executive Chairman at Cancer Genetics, Inc., a President, Chief Executive Officer & Director at Zeta Acquisition Corp. I, a President, Chief Executive Officer & Director at Zeta Acquisition Corp. II, a Chairman at American CareSource Holdings, Inc., a President & Owner at Equity Dynamics, Inc., a President & Owner at Pappajohn Capital Resources and a Chairman at e-Marine Co. Ltd. He is on the Board of Directors at MYnd Analytics, Inc., Zeta Acquisition Corp. I, Zeta Acquisition Corp. II, Advanced Analytical Technologies, Inc., Business Committee for the Arts, Inc. and State University of Iowa Foundation. Mr. Pappajohn was previously employed as a President, Chief Executive Officer & Director by Zeta Acquisition Corp. III, a Chairman by PharmAthene, Inc., a Chairman & Secretary by Healthcare Acquisition Corp., an Independent Director by Conmed Healthcare Management, Inc., a Founder by Caremark Rx, Inc., a Founder by Accredo Health Group, Inc., a Founder by Quantum Health Resources & Associates, and a Founder by Radiologix, Inc. He also served on the board at SpectraScience, Inc., CareGuide, Inc., PACE Health Management Systems, Inc., MC Informatics, Inc., Allion Healthcare, Inc. and Patient Infosystems, Inc. He received his undergraduate degree from the University of Iowa.
Edmund M. Cannon Edmund M. Cannon founded Clinical Research Center of Cape Cod, Inc. and Alletess, Inc. Presently, he occupies the position of President of Clinical Research Center of Cape Cod, Inc. Mr. Cannon is also on the board of Cancer Genetics, Inc. In the past Mr. Cannon held the position of Vice President of Alletess, Inc. and Principal at Franey Medical Labs. Mr. Cannon received a graduate degree from Providence College and an undergraduate degree from Boston College.
Geoffrey Eric Harris Geoffrey Eric Harris is Managing Partner & Portfolio Manager at C7 Advisors LLC and on the board of 7 other companies. In the past he occupied the position of Principal at Sirios Capital Management LP, Co-Head-Healthcare Investment Banking at Cantor Fitzgerald & Co., Vice President at Tucker Anthony Cleary Gull, Managing Director at UBS Asset Management (US), Inc., Portfolio Manager at CoreCommodity Management LLC, Managing Director at Broadpoint.Gleacher Asset Management, Managing Director at Gleacher & Co. Securities, Inc. and Managing Director at Broadpoint.Gleacher Securities. Mr. Harris received an undergraduate degree from Oberlin College and a graduate degree from MIT Sloan School of Management.
Franklyn G. Prendergast Dr. Franklyn G. Prendergast is an Independent Director at Cancer Genetics, Inc., a Chairman at Infectious Disease Research Institute, a Professor at Mayo Clinic College of Medicine, an Independent Director at NeuBase Therapeutics, Inc., a Member at American Cancer Society, Inc., a Member at American Chemical Society, a Member at American Society for Biochemistry & Molecular Biology, Inc., a Member at Sigma XI, a Member at The Biophysical Society and a Professor at Mayo Foundation for Medical Education & Research. He is on the Board of Directors at Medibio Ltd., Cancer Genetics, Inc., Acelerate, Inc., DemeRx, Inc., On Target Laboratories LLC, Perimeter Medical Imaging, Inc., Predictive Health Technologies, Inc. and NeuBase Therapeutics, Inc. Dr. Prendergast was previously employed as an Independent Director by Eli Lilly & Co., a Trustee by The Mayo Clinic (Old), a Member-Governors Board by Mayo Clinic Rochester, a Chairman-Biochemistry & Molecular Biology by Mayo Foundation for Medical Education & Research, a Member by American Association for the Advancement of Science, a Professor by Mayo Medical School, a Member by Molecular Biology Resources, Inc., a Principal by National Academy of Sciences, a Member-Scientific Advisory Board by National Cancer Institute, and a Principal by National Institute of Health Policy. He also served on the board at Neubase Therapeutics, Inc. /Old/, Mayo Clinic Cancer Center, Ativa Medical Corp., GMP Cos., Inc., Liquid Bioscience, Inc. and Translational Genomics Research Institute. He received his undergraduate degree from the University of Oxford, an undergraduate degree from The University of the West Indies, a graduate degree from the University of Oxford and a doctorate degree from the University of Minnesota.
Marie-Agnes Patrone-Michellod Marie-Agnes Patrone-Michellod occupies the position of Manager-Regulatory Affairs & Marketing at Cancer Genetics, Inc.
John A. Roberts Presently, John A. Roberts is President & Chief Executive Officer at Cancer Genetics, Inc. He is also Chairman-Elect at Drug Information Association. In the past he was CFO & SVP-Corporate Development at HealthOnLine, Principal at Stanley Black & Decker, Inc. and Chief Financial Officer at Infologix, Inc. (a subsidiary of Stanley Black & Decker, Inc.), Chief Financial Officer & Secretary of Daou Systems, Inc., Chief Financial Officer & Secretary of Clarient, Inc., Chief Financial & Administrative Officer at AdvantEdge Healthcare Solutions, Inc. and Vice President-Business Development of MEDecision, Inc. He received an undergraduate degree and an MBA from the University of Maine.
Raju S. K. Chaganti Founder of Cancer Genetics, Inc., Raju S. K. Chaganti is on the board of Cancer Genetics, Inc. (former Chairman) and Cancer Genetics (India) Pvt Ltd. and Professor at Gerstner Sloan Kettering Graduate School of Biomedical Science. In the past he held the position of Principal at Cell Biology & Physiology and Chief Executive Officer at Memorial Sloan-Kettering Cancer Center. He received a doctorate from Harvard University.
John A. Roberts Presently, John A. Roberts is President & Chief Executive Officer at Cancer Genetics, Inc. He is also Chairman-Elect at Drug Information Association. In the past he was CFO & SVP-Corporate Development at HealthOnLine, Principal at Stanley Black & Decker, Inc. and Chief Financial Officer at Infologix, Inc. (a subsidiary of Stanley Black & Decker, Inc.), Chief Financial Officer & Secretary of Daou Systems, Inc., Chief Financial Officer & Secretary of Clarient, Inc., Chief Financial & Administrative Officer at AdvantEdge Healthcare Solutions, Inc. and Vice President-Business Development of MEDecision, Inc. He received an undergraduate degree and an MBA from the University of Maine.
Edmund M. Cannon Edmund M. Cannon founded Clinical Research Center of Cape Cod, Inc. and Alletess, Inc. Presently, he occupies the position of President of Clinical Research Center of Cape Cod, Inc. Mr. Cannon is also on the board of Cancer Genetics, Inc. In the past Mr. Cannon held the position of Vice President of Alletess, Inc. and Principal at Franey Medical Labs. Mr. Cannon received a graduate degree from Providence College and an undergraduate degree from Boston College.
Ralf Brandt Dr. Ralf Brandt is a President-Discovery & Early Development at Cancer Genetics, Inc. and a Member-Scientific Advisory Board at Receptors, Inc. Dr. Brandt was previously employed as a President-Discovery & Early Development by vivoPharm Pty Ltd. and a Principal by National Cancer Institute. He received his undergraduate degree from Martin-Luther-Universit�0�1¤t Halle-Wittenberg and a doctorate degree from Martin-Luther-Universit�0�1¤t Halle-Wittenberg.
Edmund M. Cannon Edmund M. Cannon founded Clinical Research Center of Cape Cod, Inc. and Alletess, Inc. Presently, he occupies the position of President of Clinical Research Center of Cape Cod, Inc. Mr. Cannon is also on the board of Cancer Genetics, Inc. In the past Mr. Cannon held the position of Vice President of Alletess, Inc. and Principal at Franey Medical Labs. Mr. Cannon received a graduate degree from Providence College and an undergraduate degree from Boston College.
Pal Singh-Kahlon Pal Singh-Kahlon is Member of American Society of Human Genetics, Member of American College of Medical Genetics & Genomics, Member of Association for Molecular Pathology and Cytogenetics Director at Cancer Genetics, Inc.
Franklyn G. Prendergast Dr. Franklyn G. Prendergast is an Independent Director at Cancer Genetics, Inc., a Chairman at Infectious Disease Research Institute, a Professor at Mayo Clinic College of Medicine, an Independent Director at NeuBase Therapeutics, Inc., a Member at American Cancer Society, Inc., a Member at American Chemical Society, a Member at American Society for Biochemistry & Molecular Biology, Inc., a Member at Sigma XI, a Member at The Biophysical Society and a Professor at Mayo Foundation for Medical Education & Research. He is on the Board of Directors at Medibio Ltd., Cancer Genetics, Inc., Acelerate, Inc., DemeRx, Inc., On Target Laboratories LLC, Perimeter Medical Imaging, Inc., Predictive Health Technologies, Inc. and NeuBase Therapeutics, Inc. Dr. Prendergast was previously employed as an Independent Director by Eli Lilly & Co., a Trustee by The Mayo Clinic (Old), a Member-Governors Board by Mayo Clinic Rochester, a Chairman-Biochemistry & Molecular Biology by Mayo Foundation for Medical Education & Research, a Member by American Association for the Advancement of Science, a Professor by Mayo Medical School, a Member by Molecular Biology Resources, Inc., a Principal by National Academy of Sciences, a Member-Scientific Advisory Board by National Cancer Institute, and a Principal by National Institute of Health Policy. He also served on the board at Neubase Therapeutics, Inc. /Old/, Mayo Clinic Cancer Center, Ativa Medical Corp., GMP Cos., Inc., Liquid Bioscience, Inc. and Translational Genomics Research Institute. He received his undergraduate degree from the University of Oxford, an undergraduate degree from The University of the West Indies, a graduate degree from the University of Oxford and a doctorate degree from the University of Minnesota.
Howard McLeod Howard McLeod is on the board of Gentris Corp. and Cancer Genetics, Inc. and Director-Pharmacogenomics & Individualized at the University of North Carolina at Chapel Hill. In his past career Dr. McLeod was Medical Director of H. Lee Moffitt Cancer Center & Research Institute, Inc. and Professor at UNC Eshelman School of Pharmacy.
Howard McLeod Howard McLeod is on the board of Gentris Corp. and Cancer Genetics, Inc. and Director-Pharmacogenomics & Individualized at the University of North Carolina at Chapel Hill. In his past career Dr. McLeod was Medical Director of H. Lee Moffitt Cancer Center & Research Institute, Inc. and Professor at UNC Eshelman School of Pharmacy.
Howard McLeod Howard McLeod is on the board of Gentris Corp. and Cancer Genetics, Inc. and Director-Pharmacogenomics & Individualized at the University of North Carolina at Chapel Hill. In his past career Dr. McLeod was Medical Director of H. Lee Moffitt Cancer Center & Research Institute, Inc. and Professor at UNC Eshelman School of Pharmacy.
Howard McLeod Howard McLeod is on the board of Gentris Corp. and Cancer Genetics, Inc. and Director-Pharmacogenomics & Individualized at the University of North Carolina at Chapel Hill. In his past career Dr. McLeod was Medical Director of H. Lee Moffitt Cancer Center & Research Institute, Inc. and Professor at UNC Eshelman School of Pharmacy.
Howard McLeod Howard McLeod is on the board of Gentris Corp. and Cancer Genetics, Inc. and Director-Pharmacogenomics & Individualized at the University of North Carolina at Chapel Hill. In his past career Dr. McLeod was Medical Director of H. Lee Moffitt Cancer Center & Research Institute, Inc. and Professor at UNC Eshelman School of Pharmacy.
John A. Roberts Presently, John A. Roberts is President & Chief Executive Officer at Cancer Genetics, Inc. He is also Chairman-Elect at Drug Information Association. In the past he was CFO & SVP-Corporate Development at HealthOnLine, Principal at Stanley Black & Decker, Inc. and Chief Financial Officer at Infologix, Inc. (a subsidiary of Stanley Black & Decker, Inc.), Chief Financial Officer & Secretary of Daou Systems, Inc., Chief Financial Officer & Secretary of Clarient, Inc., Chief Financial & Administrative Officer at AdvantEdge Healthcare Solutions, Inc. and Vice President-Business Development of MEDecision, Inc. He received an undergraduate degree and an MBA from the University of Maine.
John A. Roberts Presently, John A. Roberts is President & Chief Executive Officer at Cancer Genetics, Inc. He is also Chairman-Elect at Drug Information Association. In the past he was CFO & SVP-Corporate Development at HealthOnLine, Principal at Stanley Black & Decker, Inc. and Chief Financial Officer at Infologix, Inc. (a subsidiary of Stanley Black & Decker, Inc.), Chief Financial Officer & Secretary of Daou Systems, Inc., Chief Financial Officer & Secretary of Clarient, Inc., Chief Financial & Administrative Officer at AdvantEdge Healthcare Solutions, Inc. and Vice President-Business Development of MEDecision, Inc. He received an undergraduate degree and an MBA from the University of Maine.
Michael McCartney Michael McCartney is Chief Commercial Officer at Cancer Genetics, Inc. In his past career he was Chief Operating Officer of SciKon Innovation, Inc. He received an MBA from LaSalle University and an undergraduate degree from Indiana University of Pennsylvania.
Ehab Elkhouly Ehab Elkhouly holds the position of VP-Clinical Affairs & Site Operations at Cancer Genetics, Inc. In the past Dr. Elkhouly occupied the position of Operations Director for Response Genetics, Inc. Dr. Elkhouly received an undergraduate degree from KasrAlAiny School of Medicine and a graduate degree from Paul Merage School of Business.
Glenn Miles Mr. Glenn Miles is a Chief Financial Officer at Cancer Genetics, Inc., a President & Chief Financial Officer at Catalytic Consulting LLC, a Member at American College of Healthcare Executives, a Member at Financial Executives International, a Member at Healthcare Financial Management Association and a Member at The American Institute of Certified Public Accountants. Mr. Miles was previously employed as a Controller-Developed Europe & Latin America by Pfizer Inc. and an Accountant by Grant Thornton LLP. He received his undergraduate degree from The University of Alabama and an MBA from Mercer University.
Glenn Miles Mr. Glenn Miles is a Chief Financial Officer at Cancer Genetics, Inc., a President & Chief Financial Officer at Catalytic Consulting LLC, a Member at American College of Healthcare Executives, a Member at Financial Executives International, a Member at Healthcare Financial Management Association and a Member at The American Institute of Certified Public Accountants. Mr. Miles was previously employed as a Controller-Developed Europe & Latin America by Pfizer Inc. and an Accountant by Grant Thornton LLP. He received his undergraduate degree from The University of Alabama and an MBA from Mercer University.
William Finger William Finger is EVP-Precision Medicine & Biopharma Solutions at Cancer Genetics, Inc. He received a graduate degree from the University of North Carolina at Chapel Hill and an undergraduate degree from The State University of New York.

量化对比

全部评论 4

  • 【疫苗股和血浆类股均普遍下跌】疫苗股Alpha Pro Tech跌超10%,诺瓦瓦克斯跌超9%,Inovio跌约6.0%,Moderna跌约2.3%,辉瑞制药跌约0.7%、其德国合作伙伴BioNTech也跌4.8%,阿斯利康则涨0.4%。血浆股iBio跌约10.6%,Thermogenesis跌约9.0%,Sonnet Biotherapeutics和Cancer Genetics均跌超6.5%,Liminal BioSciences和Cerus至少跌超5.6%。

  • 【疫苗股和血浆类股均普遍下跌】疫苗股Alpha Pro Tech跌超10%,诺瓦瓦克斯跌超9%,Inovio跌约6.0%,Moderna跌约2.3%,辉瑞制药跌约0.7%、其德国合作伙伴BioNTech也跌4.8%,阿斯利康则涨0.4%。血浆股iBio跌约10.6%,Thermogenesis跌约9.0%,Sonnet Biotherapeutics和Cancer Genetics均跌超6.5%,Liminal BioSciences和Cerus至少跌超5.6%。

  • 【血浆类股普跌,卫生专家们用数据否定特朗普用血浆来治疗新冠肺炎的行动】Adma Biologics下跌7.6%,Kamada跌6.7%,Liminal BioSciences跌5.3%,Sonnet Biotherapeutics跌超3.0%,Grifols跌1.7%,Cancer Genetics涨超3.7%,T2 Biosystems涨1.5%,Thermogenesis Holdings涨0.5%。美国国立卫生研究院(NIH)专家组表示,数据未能支持总统特朗普关于用血浆来治疗新冠肺炎病毒的想法,一项研究结果表明,那些接受高含量抗体的人“在为期七天的存活试验中并未出现任何治疗效果”。相比之下,美国食品药品管理局(FDA)此前表示,通过血浆治疗,死亡病例可以锐减35%。

  • 美股多只生物制药概念个股大涨,Cancer Genetics(CGIX.O)涨近150%,iBio(IBIO.O)涨45%,Sonnet BioTherapeutics(SONN.O)涨近50%,ADMA生物(ADMA.O)涨17.3%。日前美国药监局向血浆疗法授予使用紧急授权(EUA),治疗医院收治的新冠肺炎病人。

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐